Co-Founders

Jennifer L. GoodPresident and CEO

Jennifer Good is the co-founder of Trevi Therapeutics and serves as a director as well as the Company's President and Chief Executive Officer. Prior to founding Trevi, Ms. Good successfully led the transition of a publicly traded life sciences company, Penwest Pharmaceuticals Co., from a development stage company to generating annual revenues in excess of $50 million with strong profitability. The Company was acquired by its strategic partner in 2010. Ms. Good received a Bachelor of Business Administration degree with a Concentration in Accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Ms. Good currently serves on the board of the Friedreich's Ataxia Research Alliance (FARA), which is a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia. In 2007, Ms. Good received the Connecticut Technology Counsel's Small Business Innovation and Leadership Award, and was a nominee in 2014 for the Entrepreneurial Innovation and Leadership Award.

Thomas R. Sciascia, M.D.Chief Medical Officer

Thomas Sciascia, M.D. is the co-founder of Trevi Therapeutics and serves as the Company's Chief Medical Officer. Dr. Sciascia has an extensive background in clinical development and regulatory strategy. Prior to founding Trevi, Dr. Sciascia was the Sr. Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest Pharmaceuticals. Prior to working at Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharma and biotechnology companies. He also worked as a Medical Director at Transkaryotic Therapeutics. Dr. Sciascia received a Bachelors of Science Degree in Biology at Massachusetts Institute of Technology and a Medical Degree at Columbia University. He is a board certified neurologist licensed to practice medicine in the state of Massachusetts. Dr. Sciascia has numerous issued patents and is the author on several publications.

Board of Directors

Eran Nadav, Ph.D.Chairman

Eran Nadav serves as Partner and Managing Director at TPG Biotech (www.tpgbiotech.com), the life science venture investment arm of the global private investment firm TPG. He joined the firm in 2007 as Vice President, and over time assumed responsibilities to become a TPG partner. He invests in a broad range of early to late stage companies and products, including innovative therapies and high value generics.  

Prior to TPG, Dr. Nadav served as Business Development Director at Eisai, where he evaluated and negotiated notable licensing and acquisition deals. Prior to this, Dr. Nadav worked for the Israeli office of JJDC, the venture capital subsidiary of Johnson & Johnson, where he analyzed and executed investments in innovative technologies and biopharmaceuticals. Previously, Dr. Nadav worked for Neurim Pharmaceuticals Ltd. supporting the clinical development of Circadin®. He holds a Ph.D. in biochemistry, M.Sc. magna cum laude, B.Sc. magna cum laude, and MBA - all from Tel Aviv University.

Jennifer L. Good

Jennifer Good is the co-founder of Trevi Therapeutics and serves as a director as well as the Company's President and Chief Executive Officer. Prior to founding Trevi, Ms. Good successfully led the transition of a publicly traded life sciences company, Penwest Pharmaceuticals Co., from a development stage company to generating annual revenues in excess of $50 million with strong profitability. The Company was acquired by its strategic partner in 2010. Ms. Good received a Bachelor of Business Administration degree with a Concentration in Accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Ms. Good currently serves on the board of the Friedreich's Ataxia Research Alliance (FARA), which is a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia. In 2007, Ms. Good received the Connecticut Technology Counsel's Small Business Innovation and Leadership Award, and was a nominee in 2014 for the Entrepreneurial Innovation and Leadership Award.

W. James O'Shea

From October 1999 to March 2007, Mr. O'Shea was President and Chief Operating Officer at Sepracor Inc., where he was responsible for successfully building that organization's commercial infrastructure. From April to August 2007, Mr. O'Shea served as Sepracor's Vice Chairman. Prior to Sepracor, Mr. O'Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Zeneca Inc. While at Zeneca, he also held several management positions of increasing responsibility in international sales and marketing in the U.S. and U.K. Mr. O'Shea is past Chairman of the National Pharmaceutical Council and serves on the board of directors of BTG plc, Prostrakan Group plc and is the Chariman of Cardiome. Mr. O'Shea is a graduate of Liverpool Lord Byron University. He also received an honors degree in applied physics from the Institute of Physics.

Cayce Denton

Cayce Denton serves as Vice President at TPG Biotech (www.tpgbiotech.com), the life science venture investment arm of the global private investment firm TPG. Prior to joining TPG Biotechnology in 2010, Ms. Denton managed finance for the Nutropin and Lytics franchises at Genentech, Inc., where she also participated in a CFO Rotation Program consisting of time in R&D Finance, Financial Planning and Analysis, Audit and Treasury. Prior to Genentech, Inc., she was in Business Development at Novartis in Cambridge, where she helped execute an approximately $700 million partnership with Alnylam Pharmaceuticals, Inc. Prior to Novartis, Ms. Denton worked in biotech venture capital at Atlas Venture and was an investment banker with Credit Suisse First Boston’s Technology Group, in Boston. Ms. Denton has an MBA from the Wharton School of the University of Pennsylvania, where she was awarded the F. H. Shields Fellowship and co-founded the Biotech Investment Group, and a B.S. from M.I.T. in Biology.

Board Advisor

David Meeker, M.D.

David Meeker was appointed President and Chief Executive Officer of Genzyme in October 2011. Genzyme is a global biotechnology company committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs. Dr. Meeker oversees and provides the vision for the company’s two business units – Rare Diseases and Multiple Sclerosis – as well as its long-standing relationships with patient communities and dedicated workforce of nearly 10,000 employees.

In his career with Genzyme, Dr. Meeker has held key positions of increasing responsibility most recently as Chief Operating Officer. In this role, he was responsible for Genzyme’s commercial organization, overseeing its business units¸ country management organization and global market access functions.  As Chief Operating Officer, he played an important role in the integration with Sanofi.

Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of rare disease therapies that today represent transformative and life-saving advancements in medicine for patients.

Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters.

Dr. Meeker received his MD from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.

Founder's Story

Enter a founder's story here.